Remedent, Inc.
REMI · OTC
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.06 | 0.49 | 0.16 |
| FCF Yield | -7.08% | 4.64% | -2.59% | -1.56% |
| EV / EBITDA | -6.25 | 33.26 | -98.40 | -91.74 |
| Quality | ||||
| ROIC | -5.05% | 0.88% | -0.30% | -0.92% |
| Gross Margin | 63.64% | 65.67% | 58.16% | 54.00% |
| Cash Conversion Ratio | 0.42 | 2.57 | 2.63 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.40% | -3.71% | -4.56% | -7.91% |
| Free Cash Flow Growth | -199.70% | 219.34% | -46.53% | -180.68% |
| Safety | ||||
| Net Debt / EBITDA | 0.14 | -1.17 | 1.22 | 1.99 |
| Interest Coverage | 0.00 | 38.31 | -12.51 | -29.70 |
| Efficiency | ||||
| Inventory Turnover | 1.00 | 1.24 | 0.87 | 1.09 |
| Cash Conversion Cycle | -1,885.72 | -1,619.95 | -2,077.36 | -1,686.22 |